Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Vaccinations

Vaccinations

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Recombinant DNA

Recombinant DNA

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Cross-reactivity

Cross-reactivity

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PPAR<sub>α</sub> Dependent Regulation of Gut Microbiota: Implication for Host Metabolic Homeostasis.

Molecular nutrition & food research·2026

Same author

Synergistic Interaction Between HPV-16 E7 Oncoprotein and Severe Vitamin A Deficiency in Regulating Adaptive Immunity in a Preclinical Cervical Cancer Model.

Journal of medical virology·2026

Same author

The Sialomucin CD43 Drives Tuberculosis Immunopathology Across Different Host Genetic Backgrounds.

Inflammation·2026

Same author

Bacterial Fluorescence-Based Biosensor for Detecting Propionate in Culture Media for Diagnostic Applications.

Biomarker insights·2026

Same author

The Participation Of Prolactin In The Immunopathology Of Experimental Pulmonary Tuberculosis.

Neuroimmunomodulation·2026

Same author

Effect of Starch Microparticles on the Activation and Bactericidal Activity of Murine Alveolar Macrophages Infected with <i>Mycobacterium tuberculosis</i>.

Microorganisms·2026

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Recombinant BCG vaccine candidates.

Rogelio Hernàndez-Pando¹, Mauricio Castañòn, Clara Espitia

¹Experimental Pathology Section, Department of Pathology, National Institute of Medical Sciences and Nutrition Salvador Zubiràn, Mexico City, Mexico. rhpando@quetzal.innsz.mx

Current Molecular Medicine

|June 23, 2007

Summary

New recombinant BCG (rBCG) vaccines show promise for tuberculosis prevention. Researchers are exploring molecular methods to create these improved vaccines, with some now in clinical trials.

More Related Videos

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Published on: January 31, 2018

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

Related Experiment Videos

Last Updated: Jul 14, 2026

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Published on: January 31, 2018

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

Area of Science:

Vaccinology
Microbiology
Immunology

Background:

The current Mycobacterium bovis BCG vaccine has variable efficacy against tuberculosis.
Tuberculosis remains a significant global health burden, necessitating improved preventative strategies.

Purpose of the Study:

To review molecular methods for generating recombinant BCG (rBCG) vaccine candidates.
To compare the efficacy of rBCG candidates against conventional BCG in animal models.

Main Methods:

Discussion of molecular techniques employed in the development of rBCG.
Comparative analysis of rBCG vaccine performance in various animal models.

Main Results:

rBCG candidates demonstrate potential as improved tuberculosis vaccines.
Some rBCG vaccines have shown promising results in preclinical animal studies.

Conclusions:

Recombinant BCG (rBCG) represents a promising avenue for developing more effective tuberculosis vaccines.
Several rBCG candidates are advancing to human clinical trials, indicating their potential impact.